A Closer Look at Valuation as New ALK Inhibitor Data Presentation Approaches
Nuvalent (NUVL) has scheduled a webcast to present pivotal data from its Phase 1/2 ALKOVE-1 study. The presentation…
Nuvalent to Present Patient-Reported Outcomes Data from ARROS-1 Trial of ROS1-Selective Inhibitor, Zidesamtinib, at 2025 IASLC ASCO North America Conference on Lung Cancer
Encore pivotal efficacy and safety data from the ARROS-1 trial also to be presented during poster session CAMBRIDGE,…
Nuvalent to Participate in the UBS 2025 Virtual Oncology Day
CAMBRIDGE, Mass., Sept. 24, 2025 /PRNewswire/ — Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies…